Finasteride & Minoxidil

Finasteride and Minoxidil are MHRA and FDA-approved pharmaceutical therapies for pattern hair loss (androgenetic alopecia). Finasteride acts as a 5-alpha reductase inhibitor, lowering follicle-damaging dihydrotestosterone (DHT) levels, while Minoxidil acts as a potassium-channel opener that enhances microcirculation to follicle roots.

Men and suitable women with early-to-moderate pattern thinning who wish to explore proven prescription pharmacotherapy under doctor-led supervision.

Following comprehensive medical assessment, baseline health checks, and side-effect counselling, tailored topical or oral formulations are prescribed with structured 3, 6, and 12-month follow-up reviews to monitor response and tolerance.

Yes. All treatments begin with a private medical consultation so suitability and safety can be assessed individually.

Aesthetic and medical treatments may support your goals in suitable patients, with progress reviewed together. Responses vary, so identical outcomes cannot be promised.

Suitability is confirmed individually at a private consultation. Where a treatment is not appropriate, Dr Farzana will say so honestly and discuss alternatives where helpful.

Finasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone into dihydrotestosterone (DHT), preventing DHT from binding to and miniaturising susceptible hair follicles.

Minoxidil acts as a potassium-channel opener that widens scalp microvascular blood vessels, increasing oxygen and vital nutrient delivery to hair roots and prolonging the active anagen growth phase.

Adult men and selected women with early-to-moderate androgenetic alopecia (pattern hair loss) who wish to stabilise thinning and preserve follicle density. Suitability is confirmed during a private medical consultation.

Yes. Dr Farzana discusses advanced topical compounded formulations (such as topical Finasteride or Dutasteride combined with Minoxidil) that deliver active medication directly to scalp follicles while significantly minimising systemic absorption.

Follicular stabilisation begins within 3 to 6 months of consistent daily use, with noticeable density improvements and hair shaft thickening becoming apparent between 6 and 12 months.

Yes. Combining medical DHT suppression with regenerative growth factors (PRP or ASCE+ exosomes) provides a powerful dual-action synergy: medication prevents further follicle shrinkage while regenerative therapy actively revitalises dormant roots.